Patents by Inventor Jurgen Eckel

Jurgen Eckel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
    Patent number: 9345741
    Abstract: The present disclosure relates to nutritional compositions including a protein equivalent source that includes a peptide component comprising selected peptides. The protein equivalent source may further include intact protein, hydrolyzed protein, including partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of promoting healthy body weight in a target subject by stimulating adiponectin levels by providing the nutritional compositions disclosed herein to a target subject, which includes a pediatric subject.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 24, 2016
    Assignee: Mead Johnson Nutrition Company
    Inventors: Dirk Hondmann, Eric A. F. Van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers, Tania Ramacho, Manuela Elsen, Jürgen Eckel
  • Activating adiponectin by casein hydrolysate
    Patent number: 9138455
    Abstract: The present disclosure provides a method for activating adiponectin by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce risk of heart attack and help in maintaining healthy weight. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 22, 2015
    Assignee: Mead Johnson Nutrition Company
    Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers, Tania Romacho, Manuela Elsen, Jürgen Eckel
  • Method for identifying IRS inhibitors or agonists
    Patent number: 7803571
    Abstract: The present invention relates to a method for the identification of an IRS protein kinase inhibitor, comprising the steps of a) bringing into contact PKC-? with at least one IRS peptide comprising at least one PKC-?-Ser-phosphorylation site in the presence of at least one possible inhibitor, and b) measuring the phosphorylation of the PKC-?-Ser-phosphorylation site.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: September 28, 2010
    Assignee: Sanfoi-Aventis Deutschland GmbH
    Inventors: Norbert Tennagels, Jurgen Eckel, Sabine Metzger, Mark Sommerfeld
  • Method of activating insulin receptor substrate-2 to stimulate insulin production
    Publication number: 20050250676
    Abstract: The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LysB3,GluB29 insulin to patients in need of this treatment.
    Type: Application
    Filed: July 11, 2005
    Publication date: November 10, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Seipke, Irini Rakatzi, Olaf Dransfeld, Jurgen Eckel
  • Method for the identification of IRS protein kinase inhibitors or agonist
    Publication number: 20050106653
    Abstract: The present invention relates to a method for the identification of an IRS protein kinase inhibitor, comprising the steps of a) bringing into contact PKC-? with at least one IRS peptide comprising at least one PKC-?-Ser-phosphorylation site in the presence of at least one possible inhibitor, and b) measuring the phosphorylation of the PKC-?-Ser-phosphorylation site.
    Type: Application
    Filed: August 13, 2004
    Publication date: May 19, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Norbert Tennagels, Jurgen Eckel, Sabine Metzger, Mark Sommerfeld